[{"id":"34339220-1770-4108-8649-484d7d43cefa","acronym":"212-Pb-VMT","url":"https://clinicaltrials.gov/study/NCT05636618","created_at":"2022-12-05T15:56:36.062Z","updated_at":"2025-02-25T17:38:15.153Z","phase":"Phase 1/2","brief_title":"Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors","source_id_and_acronym":"NCT05636618 - 212-Pb-VMT","lead_sponsor":"Perspective Therapeutics","biomarkers":" SSTR • CD4 • SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR2 positive","tags":["SSTR • CD4 • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VMT-𝛼-NET"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 09/27/2023","start_date":" 09/27/2023","primary_txt":" Primary completion: 11/26/2029","primary_completion_date":" 11/26/2029","study_txt":" Completion: 12/26/2029","study_completion_date":" 12/26/2029","last_update_posted":"2025-01-29"},{"id":"788d5186-c5e0-4cdd-ba52-51d8b5d8095b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04544098","created_at":"2021-02-11T16:55:22.383Z","updated_at":"2024-07-02T16:35:06.529Z","phase":"Phase 1","brief_title":"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver","source_id_and_acronym":"NCT04544098","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-02"},{"id":"9461158e-5d26-4049-990e-1b882bc14200","acronym":"","url":"https://clinicaltrials.gov/study/NCT06295952","created_at":"2024-03-06T21:33:56.543Z","updated_at":"2024-07-02T16:35:06.703Z","phase":"Phase 2","brief_title":"A Study of Pasireotide in People With Prolactinoma","source_id_and_acronym":"NCT06295952","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PRL","pipe":"","alterations":" ","tags":["PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Signifor (pasireotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/27/2024","start_date":" 02/27/2024","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-05-01"},{"id":"5cfe778d-fe5e-47ad-9d92-bcdc82f98727","acronym":"SORENTO","url":"https://clinicaltrials.gov/study/NCT05050942","created_at":"2021-09-21T11:53:31.080Z","updated_at":"2024-07-02T16:35:22.027Z","phase":"Phase 3","brief_title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","source_id_and_acronym":"NCT05050942 - SORENTO","lead_sponsor":"Camurus AB","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous • Oclaiz (octreotide subcutaneous depot) • octreotide acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 332","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-26"},{"id":"86e6304f-18fe-45fe-88fc-ade5048e2472","acronym":"AIM-NETs","url":"https://clinicaltrials.gov/study/NCT04696042","created_at":"2021-01-19T20:49:35.455Z","updated_at":"2024-07-02T16:35:42.517Z","phase":"","brief_title":"Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs","source_id_and_acronym":"NCT04696042 - AIM-NETs","lead_sponsor":"Asan Medical Center","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 01/30/2024","primary_completion_date":" 01/30/2024","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2023-07-19"},{"id":"34bbec34-4daa-4d0a-80bd-efb11de7e324","acronym":"PALACE","url":"https://clinicaltrials.gov/study/NCT04852679","created_at":"2021-04-21T11:53:31.620Z","updated_at":"2024-07-02T16:35:57.483Z","phase":"Phase 3","brief_title":"Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs","source_id_and_acronym":"NCT04852679 - PALACE","lead_sponsor":"Ipsen","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 05/24/2021","start_date":" 05/24/2021","primary_txt":" Primary completion: 06/10/2022","primary_completion_date":" 06/10/2022","study_txt":" Completion: 01/13/2023","study_completion_date":" 01/13/2023","last_update_posted":"2023-01-18"},{"id":"058d1321-7be9-48a4-947c-65800088332e","acronym":"CLARINET","url":"https://clinicaltrials.gov/study/NCT00353496","created_at":"2021-01-18T01:13:26.014Z","updated_at":"2024-07-02T16:36:02.649Z","phase":"Phase 3","brief_title":"Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours","source_id_and_acronym":"NCT00353496 - CLARINET","lead_sponsor":"Ipsen","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 264","initiation":"Initiation: 06/01/2006","start_date":" 06/01/2006","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 04/01/2013","study_completion_date":" 04/01/2013","last_update_posted":"2022-10-11"},{"id":"d8d92c20-f9b0-4b65-887c-9b325e1515f6","acronym":"LAMPARA","url":"https://clinicaltrials.gov/study/NCT03946527","created_at":"2021-01-18T19:25:49.115Z","updated_at":"2024-07-02T16:36:02.836Z","phase":"Phase 2","brief_title":"LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)","source_id_and_acronym":"NCT03946527 - LAMPARA","lead_sponsor":"Antonio Fojo","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/17/2019","start_date":" 06/17/2019","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-10-07"},{"id":"1c7411aa-3958-4e55-a6f9-57809423a865","acronym":"CLARINET FORTE","url":"https://clinicaltrials.gov/study/NCT02651987","created_at":"2021-01-18T12:54:41.991Z","updated_at":"2024-07-02T16:36:03.082Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg","source_id_and_acronym":"NCT02651987 - CLARINET FORTE","lead_sponsor":"Ipsen","biomarkers":" SSTR • GAST • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • GAST • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 99","initiation":"Initiation: 12/15/2015","start_date":" 12/15/2015","primary_txt":" Primary completion: 10/16/2019","primary_completion_date":" 10/16/2019","study_txt":" Completion: 10/24/2019","study_completion_date":" 10/24/2019","last_update_posted":"2022-10-03"},{"id":"1ae2a3a3-6728-4257-87af-f63fd6f956aa","acronym":"NETTER-1","url":"https://clinicaltrials.gov/study/NCT01578239","created_at":"2021-01-18T06:42:58.061Z","updated_at":"2024-07-02T16:36:14.196Z","phase":"Phase 3","brief_title":"A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours","source_id_and_acronym":"NCT01578239 - NETTER-1","lead_sponsor":"Advanced Accelerator Applications","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • octreotide acetate"],"overall_status":"Completed","enrollment":" Enrollment 231","initiation":"Initiation: 09/06/2012","start_date":" 09/06/2012","primary_txt":" Primary completion: 07/31/2015","primary_completion_date":" 07/31/2015","study_txt":" Completion: 01/18/2021","study_completion_date":" 01/18/2021","last_update_posted":"2022-04-04"},{"id":"00cc47d8-1c20-4772-a6e0-095c73bd04fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02215070","created_at":"2021-01-18T10:22:57.748Z","updated_at":"2024-07-02T16:36:20.585Z","phase":"Phase 2","brief_title":"Pasireotide in Prevention of GI Toxicity","source_id_and_acronym":"NCT02215070","lead_sponsor":"Anthony Sung, MD","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 01/21/2015","start_date":" 01/21/2015","primary_txt":" Primary completion: 02/28/2019","primary_completion_date":" 02/28/2019","study_txt":" Completion: 10/15/2019","study_completion_date":" 10/15/2019","last_update_posted":"2021-11-17"},{"id":"cb54d783-3aff-40e1-81ee-683128ab09b0","acronym":"MetNET1","url":"https://clinicaltrials.gov/study/NCT02294006","created_at":"2021-06-10T09:54:24.459Z","updated_at":"2024-07-02T16:36:24.698Z","phase":"Phase 2","brief_title":"Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs","source_id_and_acronym":"NCT02294006 - MetNET1","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • metformin • octreotide acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2021-09-09"},{"id":"9ee7a7c0-245d-4c14-9519-3dfa25026101","acronym":"MetNET-2","url":"https://clinicaltrials.gov/study/NCT02823691","created_at":"2021-03-16T19:52:25.378Z","updated_at":"2024-07-02T16:36:29.449Z","phase":"Phase 1","brief_title":"The MetNET-2 Trial","source_id_and_acronym":"NCT02823691 - MetNET-2","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" SSTR2","pipe":"","alterations":" ","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin • lanreotide prolonged-release subcutaneous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-06-07"},{"id":"a6d2ab39-a519-4fdb-aca6-2f51916bba32","acronym":"","url":"https://clinicaltrials.gov/study/NCT01468532","created_at":"2021-01-18T06:06:48.742Z","updated_at":"2024-07-02T16:36:32.814Z","phase":"Phase 1/2","brief_title":"Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","source_id_and_acronym":"NCT01468532","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" IGF1 • CHGA","pipe":"","alterations":" ","tags":["IGF1 • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • prednisone • Signifor (pasireotide) • Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 07/20/2017","primary_completion_date":" 07/20/2017","study_txt":" Completion: 07/20/2017","study_completion_date":" 07/20/2017","last_update_posted":"2021-03-25"},{"id":"3bea20a1-a979-4959-b4e2-6a88db539ae8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00446082","created_at":"2021-01-18T01:34:38.995Z","updated_at":"2024-07-02T16:36:37.050Z","phase":"Phase 1","brief_title":"Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease","source_id_and_acronym":"NCT00446082","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" IGF1 • CHGA","pipe":" | ","alterations":" IGF1 elevation","tags":["IGF1 • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGF1 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 06/01/2006","start_date":" 06/01/2006","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":" Completion: 11/01/2013","study_completion_date":" 11/01/2013","last_update_posted":"2020-12-21"},{"id":"95042f6a-45be-4701-aa7b-d23a629aa6c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01652547","created_at":"2021-01-18T07:07:16.540Z","updated_at":"2024-07-02T16:36:37.035Z","phase":"Phase 1","brief_title":"A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma","source_id_and_acronym":"NCT01652547","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CCND1 • S100B","pipe":"","alterations":" ","tags":["CCND1 • S100B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 11/01/2012","start_date":" 11/01/2012","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2020-12-21"},{"id":"eb761fb6-c868-447b-b376-77638b3bacc8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01646684","created_at":"2021-01-18T07:05:32.698Z","updated_at":"2024-07-02T16:36:37.058Z","phase":"Phase 1","brief_title":"Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT01646684","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 03/08/2013","start_date":" 03/08/2013","primary_txt":" Primary completion: 11/13/2018","primary_completion_date":" 11/13/2018","study_txt":" Completion: 11/13/2018","study_completion_date":" 11/13/2018","last_update_posted":"2020-12-21"},{"id":"92cb7e06-c38e-40eb-ad94-d0480d7e3999","acronym":"ATLANT","url":"https://clinicaltrials.gov/study/NCT02698410","created_at":"2021-01-18T13:10:24.095Z","updated_at":"2024-07-02T16:36:40.479Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.","source_id_and_acronym":"NCT02698410 - ATLANT","lead_sponsor":"Ipsen","biomarkers":" HER-2 • MGMT • SSTR • SSTR2","pipe":" | ","alterations":" MGMT expression","tags":["HER-2 • MGMT • SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 02/08/2019","primary_completion_date":" 02/08/2019","study_txt":" Completion: 06/18/2019","study_completion_date":" 06/18/2019","last_update_posted":"2020-10-01"},{"id":"fd497a08-eccf-47d3-825c-09547d7fe8a1","acronym":"CALM-NET","url":"https://clinicaltrials.gov/study/NCT02075606","created_at":"2021-01-18T09:33:55.162Z","updated_at":"2024-07-02T16:36:59.020Z","phase":"Phase 4","brief_title":"Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients","source_id_and_acronym":"NCT02075606 - CALM-NET","lead_sponsor":"Ipsen","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2019-06-07"},{"id":"5e79e518-b7e4-4b68-a2bf-4b86ff88ab2c","acronym":"SONNET","url":"https://clinicaltrials.gov/study/NCT02231762","created_at":"2021-01-18T10:28:13.866Z","updated_at":"2024-07-02T16:36:59.921Z","phase":"Phase 2","brief_title":"Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET","source_id_and_acronym":"NCT02231762 - SONNET","lead_sponsor":"Ipsen","biomarkers":" SSTR","pipe":" | ","alterations":" MGMT expression • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT expression • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2019-05-06"},{"id":"ce540c17-ccf2-4643-bcd9-84218b6de1fa","acronym":"Passion I","url":"https://clinicaltrials.gov/study/NCT01283542","created_at":"2021-02-09T07:54:16.394Z","updated_at":"2024-07-02T16:37:00.170Z","phase":"Phase 2","brief_title":"Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.","source_id_and_acronym":"NCT01283542 - Passion I","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 11/26/2012","start_date":" 11/26/2012","primary_txt":" Primary completion: 09/12/2017","primary_completion_date":" 09/12/2017","study_txt":" Completion: 09/12/2017","study_completion_date":" 09/12/2017","last_update_posted":"2019-04-26"},{"id":"2a2dc230-140f-4a20-96d8-ecd219e2c801","acronym":"SOPRANo","url":"https://clinicaltrials.gov/study/NCT01840449","created_at":"2021-01-18T08:11:56.882Z","updated_at":"2024-07-02T16:37:03.875Z","phase":"","brief_title":"Somatuline Predictive Factors in Acromegaly and NET","source_id_and_acronym":"NCT01840449 - SOPRANo","lead_sponsor":"Ipsen","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 156","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 05/01/2017","study_completion_date":" 05/01/2017","last_update_posted":"2019-01-14"},{"id":"dcf070b8-c1c9-42c7-86fb-590929bf423e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02299089","created_at":"2021-01-18T10:50:48.870Z","updated_at":"2025-02-25T15:42:05.057Z","phase":"Phase 2","brief_title":"Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)","source_id_and_acronym":"NCT02299089","lead_sponsor":"Camurus AB","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Oclaiz (octreotide subcutaneous depot) • octreotide acetate • octreotide acetate solution for injection"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2017-12-15"},{"id":"97cb39b3-aeeb-4a62-883e-9aa3b0114e3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00859040","created_at":"2021-02-02T07:52:11.180Z","updated_at":"2025-02-25T15:49:58.207Z","phase":"Phase 2","brief_title":"Monthly SOM230C for Recurrent or Progressive Meningioma","source_id_and_acronym":"NCT00859040","lead_sponsor":"Patrick Y. Wen, MD","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 03/01/2009","start_date":" 03/01/2009","primary_txt":" Primary completion: 12/01/2011","primary_completion_date":" 12/01/2011","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2017-10-27"}]